Related references
Note: Only part of the references are listed.Atrial fibrillation in fracture patients treated with oral bisphosphonates
B. Abrahamsen et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Use of alendronate and risk of incident atrial fibrillation in women
Susan R. Heckbert et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Rene Rizzoli et al.
BONE (2008)
Alendronate for the treatment of osteoporosis in men
W. P. Olszynski et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Use of bisphosphonates among women and risk of atrial-fibrillation and flutter: population based case-control study
Henrik Toft Sorensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial
C. C. Mok et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome
N. Yarom et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
E. Canalis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate and atrial fibrillation
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hepatotoxicity induced by alendronate therapy
B. Yanik et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
JD Ringe et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
JP Devogelaer et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Multiparameter evidence synthesis in epidemiology and medical decision-making: current approaches
AE Ades et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY (2006)
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
CH Chesnut et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins
RE Hewitt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Alendronate-induced auditory hallucinations and visual disturbances
CI Coleman et al.
PHARMACOTHERAPY (2004)
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis
R Recker et al.
BONE (2004)
Inflammation as a risk factor for atrial fibrillation
RJ Aviles et al.
CIRCULATION (2003)
Assessment of mortality in patients enrolled in a risedronate clinical trial program: A retrospective cohort study
M Steinbuch et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2002)
Alendronate for the treatment of osteoporosis in men
E Orwoll et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Molecular basis of electrical remodeling in atrial fibrillation
DR Van Wagoner et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2000)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)